12 January 2024
The Swiss Federal Audit Office (SFAO) gives Swissmedic a doubly good report
The SFAO conducted audits of two core processes at Swissmedic between November 2022 and July 2023. In both cases, Swissmedic received very good ratings. Swissmedic is well positioned for both the authorisation and vigilance of medicinal products, has a very good international network, and has efficient, properly functioning processes that are under constant development. Swissmedic accepts the recommendations, some of which have already been included in its strategic objectives for 2023-2026.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting